Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004895
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2000-03-07
Brief Title:
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Octreotide for Palliation of Inoperable Bowel Obstruction A Phase II Study
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably
PURPOSE Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery
PURPOSE Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery
Detailed Description:
OBJECTIVES
Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer
Characterize the dose and tolerability of octreotide in this patient population
OUTLINE Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5
Patients who respond well to study may continue octreotide for palliative effects
PROJECTED ACCRUAL A total of 9-25 patients will be accrued for this study over 9 months
Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer
Characterize the dose and tolerability of octreotide in this patient population
OUTLINE Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5
Patients who respond well to study may continue octreotide for palliative effects
PROJECTED ACCRUAL A total of 9-25 patients will be accrued for this study over 9 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1685 | None | None | None |
| NU-97X1 | None | None | None |